Explore more publications!

Comoros Technology Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Comoros Technology Digest.

Press releases published on March 16, 2026

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
Real Messenger Announces Receipt of Nasdaq Notification Letter Regarding Minimum Price Deficiency
SAIC Announces Fourth Quarter and Full Fiscal Year 2026 Results
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
VivoPower Announces Effectiveness of New Stock Ticker “VIVO” and Corporate Name Change
Clarios Appoints Chris Courts as Chief Legal Officer
Bloomway AI Announces Public Beta of CinePro: Infusing Cinematic Expertise into AIGC to Redefine the "Lean Cinema" Workflow
Cronos Group Inc. to Speak at the 38th Annual ROTH Conference
nCino Launches Doc VOI to Help Lenders Automate Document-based Income Verification
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
MediciNova to Participate at the 38th Annual ROTH Conference
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Tilray Brands Enters Agreement to Acquire BrewDog’s Key U.S. Assets, Expanding Its U.S. Craft Beer Platform
GigaCloud Technology Inc to Participate in 38th Annual Roth Conference
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions